INS and type 2 diabetes mellitus: The EDITION 3 trial was a 6 mo, multicenter, multinational, randomized, two-arm parallel-group, open-label study, comparing the efficacy and safety of Glar-300 and Glar-100 in insulin-naïve patients with T2DM not adequately controlled with noninsulin antihyperglycemic drugs, with a 6 mo safety extension period.